Julianne B Scanlan, MSPT | |
652 Rickard Hill Rd, Schoharie, NY 12157-3818 | |
(518) 295-7617 | |
Not Available |
Full Name | Julianne B Scanlan |
---|---|
Gender | Female |
Speciality | Physical Therapist - Pediatrics |
Location | 652 Rickard Hill Rd, Schoharie, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497050827 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2251P0200X | Physical Therapist - Pediatrics | 021020-1 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Julianne B Scanlan, MSPT 652 Rickard Hill Rd, Schoharie, NY 12157-3818 Ph: () - | Julianne B Scanlan, MSPT 652 Rickard Hill Rd, Schoharie, NY 12157-3818 Ph: (518) 295-7617 |
News Archive
A chart prepared by AIDS Healthcare Foundation (AHF), which provides AIDS care and treatment services to more than 79,000 individuals in 20 countries worldwide, shows how the Senate version of legislation to re-authorize PEPFAR (the President's Emergency Plan for AIDS Relief), the successful US global AIDS program, will be able to save five to seven million lives over the next five years.
The demand for Gilead Sciences' Sovaldi, which costs $1,000 a pill, indicates how hard it is for insurers to curb the use of life-saving medicines. Meanwhile Humana names a former Goldman Sachs executive as finance chief.
TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed brand name Invossa for TissueGene-C, the Company's proprietary product in development for treatment of osteoarthritis of the knee. FDA's acceptance of the proprietary brand name is subject to the Agency's final determination prior to any approval of the product's Biologic License Application (BLA) and market launch.
This World Sepsis Day, the UK Sepsis Trust is calling for people to better understand the signs and symptoms of sepsis and recognize it as a medical emergency, in order to reduce the risk of death and mitigate against the very real long-term health effects of post-sepsis syndrome.
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
› Verified 2 days ago
Mrs. Cynthia Winslow Godbout, RPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 121 Opportunity Drive, Schoharie, NY 12157 Phone: 518-295-8130 Fax: 518-295-8969 |